Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 16Myeloid 4Thoracic 1Plasma cell 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Dexamethasone 136Lenalidomide 83daratumumab 75Bortezomib 65Cyclophosphamide 49pomalidomide 46carfilzomib 45Calcium Dobesilate 42Specimen Handling 35Biopsy 32Magnetic Resonance Spectroscopy 29belantamab mafodotin 26fludarabine 23isatuximab 21talquetamab 19dexamethasone acetate 19dexamethasone 21-phosphate 19auricularum 19iberdomide 18Melphalan 17fludarabine phosphate 14elotuzumab 12selinexor 10X-Rays 10tocilizumab 9Nivolumab 8trametinib 7Whole-Body Irradiation 7Sirolimus 7Crizotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
gilteritinib × Plasma cell × 90 days × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡